U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Subscribe To Our Newsletter & Stay Updated